These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35314780)

  • 1. Spacer prioritization in CRISPR-Cas9 immunity is enabled by the leader RNA.
    Liao C; Sharma S; Svensson SL; Kibe A; Weinberg Z; Alkhnbashi OS; Bischler T; Backofen R; Caliskan N; Sharma CM; Beisel CL
    Nat Microbiol; 2022 Apr; 7(4):530-541. PubMed ID: 35314780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus.
    Karvelis T; Gasiunas G; Miksys A; Barrangou R; Horvath P; Siksnys V
    RNA Biol; 2013 May; 10(5):841-51. PubMed ID: 23535272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas Systems Optimize Their Immune Response by Specifying the Site of Spacer Integration.
    McGinn J; Marraffini LA
    Mol Cell; 2016 Nov; 64(3):616-623. PubMed ID: 27618488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential requirements for the detection and degradation of invaders by the Haloferax volcanii CRISPR/Cas system I-B.
    Maier LK; Lange SJ; Stoll B; Haas KA; Fischer S; Fischer E; Duchardt-Ferner E; Wöhnert J; Backofen R; Marchfelder A
    RNA Biol; 2013 May; 10(5):865-74. PubMed ID: 23594992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.
    Xiao Y; Ng S; Nam KH; Ke A
    Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spacer Acquisition Rates Determine the Immunological Diversity of the Type II CRISPR-Cas Immune Response.
    Heler R; Wright AV; Vucelja M; Doudna JA; Marraffini LA
    Cell Host Microbe; 2019 Feb; 25(2):242-249.e3. PubMed ID: 30709780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-cleavage activity of Cas6b in crRNA processing of two different CRISPR-Cas systems in Methanosarcina mazei Gö1.
    Nickel L; Ulbricht A; Alkhnbashi OS; Förstner KU; Cassidy L; Weidenbach K; Backofen R; Schmitz RA
    RNA Biol; 2019 Apr; 16(4):492-503. PubMed ID: 30153081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.
    Hoikkala V; Ravantti J; Díez-Villaseñor C; Tiirola M; Conrad RA; McBride MJ; Moineau S; Sundberg LR
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primed CRISPR DNA uptake in Pyrococcus furiosus.
    Garrett S; Shiimori M; Watts EA; Clark L; Graveley BR; Terns MP
    Nucleic Acids Res; 2020 Jun; 48(11):6120-6135. PubMed ID: 32421777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tracrRNA in CRISPR Biology and Technologies.
    Liao C; Beisel CL
    Annu Rev Genet; 2021 Nov; 55():161-181. PubMed ID: 34416117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.
    Silas S; Makarova KS; Shmakov S; Páez-Espino D; Mohr G; Liu Y; Davison M; Roux S; Krishnamurthy SR; Fu BXH; Hansen LL; Wang D; Sullivan MB; Millard A; Clokie MR; Bhaya D; Lambowitz AM; Kyrpides NC; Koonin EV; Fire AZ
    mBio; 2017 Jul; 8(4):. PubMed ID: 28698278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foreign DNA acquisition by the I-F CRISPR-Cas system requires all components of the interference machinery.
    Vorontsova D; Datsenko KA; Medvedeva S; Bondy-Denomy J; Savitskaya EE; Pougach K; Logacheva M; Wiedenheft B; Davidson AR; Severinov K; Semenova E
    Nucleic Acids Res; 2015 Dec; 43(22):10848-60. PubMed ID: 26586803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.
    Fonfara I; Le Rhun A; Chylinski K; Makarova KS; Lécrivain AL; Bzdrenga J; Koonin EV; Charpentier E
    Nucleic Acids Res; 2014 Feb; 42(4):2577-90. PubMed ID: 24270795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different modes of spacer acquisition by the Staphylococcus epidermidis type III-A CRISPR-Cas system.
    Aviram N; Thornal AN; Zeevi D; Marraffini LA
    Nucleic Acids Res; 2022 Feb; 50(3):1661-1672. PubMed ID: 35048966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cas6e ribonuclease is not required for interference and adaptation by the E. coli type I-E CRISPR-Cas system.
    Semenova E; Kuznedelov K; Datsenko KA; Boudry PM; Savitskaya EE; Medvedeva S; Beloglazova N; Logacheva M; Yakunin AF; Severinov K
    Nucleic Acids Res; 2015 Jul; 43(12):6049-61. PubMed ID: 26013814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Origins and Specific Evolution of CRISPR/Cas9 Systems in Minimal Bacteria (
    Ipoutcha T; Tsarmpopoulos I; Talenton V; Gaspin C; Moisan A; Walker CA; Brownlie J; Blanchard A; Thebault P; Sirand-Pugnet P
    Front Microbiol; 2019; 10():2701. PubMed ID: 31824468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cas9 interaction with the tracrRNA nexus modulates the repression of type II-A CRISPR-cas genes.
    Kim H; Marraffini LA
    Nucleic Acids Res; 2024 Sep; 52(17):10595-10606. PubMed ID: 38994567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.